News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • CMS finalized a 2.48% increase to 2027 Medicare Advantage payments, adding about $13 billion and boosting private-plan revenues.
  • Humana and other insurer shares jumped in after-hours trading on the CMS announcement.
  • President Trump threatened jail for a reporter over a leak about an Iran airman rescue, raising political and press risk.
  • U.S. equities closed higher, led by consumer, energy and technology gains, signaling a modest risk-on market tone.
  • Apogee Acquisition priced a $150 million IPO of units at $10 on Nasdaq.
  • Owlet named co-founder Kurt Workman CEO, shares rose 8% after-hours and the company reaffirmed high-end Q1 guidance.

Latest Articles

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a reimbursement coverage agreement with Highmark for its CNSide CSF Tumor Cell Enumeration assay, increasing total covered lives from approximately 67 million to 75 million. This expands patient access and supports broader adoption of CNSide in the detection and monitoring of met…

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Bio announced it received a U.S. patent covering the use of its investigational drug buntanetap in preventing and treating neurological injuries caused by brain infections, including those linked to Alzheimer's disease. The patent extends through 2044 and covers both preventive and therapeutic applications against a range of infectious agen…

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics announced inducement stock option grants to two new employees, totaling 52,450 shares at an exercise price of $6.39 per share. The options vest over four years with a ten-year term, granted to attract talent under Nasdaq inducement rules. Cartesian is advancing its lead CAR-T therapy, Descartes-08, in clinical trials for auto…

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Adagene Inc., a clinical-stage biotech company specializing in novel antibody-based cancer immunotherapies, announced the pricing of an underwritten public offering of 18.67 million ADSs at $3.75 each, raising gross proceeds of approximately $70 million. The offering attracted participation from both new and existing institutional investors and is …

Oportun Provides Updates on Leadership Transition

Oportun Provides Updates on Leadership Transition

Oportun Financial Corporation announced that Kate Layton and Gaurav Rana will serve as interim co-CEOs following the departure of CEO Raul Vazquez. Both executives will retain their current roles while leading the company during the CEO search. Vazquez will continue as an advisor until July 2026 to facilitate a smooth transition. The board is activ…

Freight Technologies Announces Strategic Update on Transition to AI-Powered, Software-First Logistics Technology Company

Freight Technologies Announces Strategic Update on Transition to AI-Powered, Software-First Logistics Technology Company

Freight Technologies announced significant progress in transforming into a software-first, AI-native logistics technology company, focusing on scaling its AI-powered platforms like Fleet Rocket, Zayren, and Fr8Radar. The company is exploring strategic alternatives for its traditional brokerage operations to concentrate resources on its AI software …

Scorpio Tankers Inc. Announces Strategic Collaboration with AMPERA, Inc. to Develop & Commercialize Micronuclear Solutions for Global Marine and Shipping Markets

Scorpio Tankers Inc. Announces Strategic Collaboration with AMPERA, Inc. to Develop & Commercialize Micronuclear Solutions for Global Marine and Shipping Markets

Scorpio Tankers Inc. has entered into a strategic collaboration with AMPERA, Inc. to jointly develop and commercialize advanced micronuclear power solutions aimed at powering maritime vessels, offshore, and port infrastructure with zero carbon emissions. The collaboration focuses on deploying ultra-safe micro nuclear reactors, including floating nu…

Burning Rock Announces Founder’s Purchase of Its ADSs

Burning Rock Announces Founder’s Purchase of Its ADSs

Burning Rock Biotech Limited announced that founder, chairman, and CEO Yusheng Han purchased 31,487 American Depositary Shares (ADSs) for $546,603.90 on the open market, adding to prior purchases this year. These transactions signal strong insider confidence in the company's precision oncology business, which focuses on next generation sequencing (…

Acuity Reports Fiscal 2026 Second-Quarter Results

Acuity Reports Fiscal 2026 Second-Quarter Results

Acuity Inc. delivered a robust second-quarter fiscal 2026 performance marked by 5% net sales growth to $1.1 billion, 21% increase in operating profit to $133 million, and a 26% rise in diluted EPS to $3.09. The company's two business segments had mixed results: Acuity Brands Lighting sales slightly declined by 2.8%, while Acuity Intelligent Spaces …

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Roivant Sciences announced the expansion of its brepocitinib development program to include a new seamless Phase 2b/3 clinical trial for the inflammatory scalp disorder lichen planopilaris (LPP), which currently has no FDA-approved treatments. Concurrently, Roivant reported topline results from Immunovant's Phase 3 studies of batoclimab in thyroid …

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Priovant Therapeutics announced the initiation of a seamless Phase 2b/3 clinical trial for brepocitinib in treating Lichen Planopilaris (LPP), a severe inflammatory scalp disorder with no FDA-approved treatments. This marks the fourth indication in brepocitinib's late-stage development alongside dermatomyositis, non-infectious uveitis, and cutaneou…

Futu Announces Cash Dividend

Futu Announces Cash Dividend

Futu Holdings Limited, a Nasdaq-listed online brokerage and wealth management platform, declared a cash dividend of $0.325 per ordinary share (equivalent to $2.6 per American Depositary Share), totaling approximately $365 million, payable to shareholders as of April 16, 2026, with payment expected around April 29, 2026.

Seven-Month-Old Killed by Stray Gunfire in Brooklyn; Suspect in Custody

Seven-Month-Old Killed by Stray Gunfire in Brooklyn; Suspect in Custody

A 7-month-old girl riding in a stroller was shot and killed on a Brooklyn street during an apparent gang-related exchange of gunfire. City officials say the child was an unintended target; one suspect has been taken into custody and police continue to seek a second man seen fleeing the scene on a moped.

Administration Plans Steep Tariffs for Drugmakers Lacking U.S. Pricing Deals

Administration Plans Steep Tariffs for Drugmakers Lacking U.S. Pricing Deals

U.S. officials are preparing to announce tariffs on pharmaceutical companies that have not struck deals to guarantee lower prices domestically, with a potential 100% tariff on imported branded and patented medicines. Some multinational drugmakers have negotiated exemptions by committing to pricing arrangements and U.S. investment, while others have…

MediaAlpha Director Sells 12,000 Shares in Three Trades to Cover RSU Taxes

MediaAlpha Director Sells 12,000 Shares in Three Trades to Cover RSU Taxes

MediaAlpha director Steven Yi reported the sale of 12,000 shares of Class A common stock across three trades from March 30 to April 1, 2026, raising $111,907. The transactions, disclosed on a Form 4 filing, were executed under a Rule 10b5-1 trading plan to cover tax liabilities from vested restricted stock units. The company recently posted Q4 2025…